✣OncoGonFROM DISCOVERY TO IMPACT
HomeAssetsTriage & Prioritisation
3D Tumour IntelligenceExperimentsImagingSegmentation & QCResponse AnalysisAI Analysis (OSIEL)
Qualified AssetsIndustry & Data RoomCollaborationReports & Insights
Admin
HomeTriage & Prioritisation
Loading triage workspace…
PORTFOLIO DECISIONS

Triage & Prioritisation

Evaluate scientific evidence, readiness, uncertainty, and validation priorities across the research portfolio.

Awaiting Triage24Portfolio queue
Under Review11Human review active
High Priority8Recommendation only
Evidence Gaps17Open actions
Ready for Validation6Reviewed candidates
Triage scores and recommendations. Scientific and commercial priority requires human review.AI recommendation ≠ human approval

Portfolio Triage Queue

10 portfolio assets · scores are inspectable research values

AssetCancer IndicationScientific ScoreEvidence ScoreNovelty3D ReadinessCommercial PotentialUncertaintyPriorityReviewerNext Action
OGC-2401Novel small moleculeBreast CancerLowHigh PriorityDr. S. Mokoena
OGC-BC-118Selective inhibitorBreast CancerMediumReviewDr. J. Patel
OGC-IM-009ImmunomodulatorMelanomaHighNeeds EvidenceDr. L. Chen
OGC-NS-321CNS penetrant agentGlioblastomaMediumHigh PriorityDr. M. Rossi
OGC-LU-104Targeted degraderLung CancerMediumReviewDr. A. Kumar
OGC-2401Novel small molecule · Breast CancerHigh PriorityScientificEvidenceNovelty3D ReadinessCommercial PotentialContinue 3D validation
OGC-BC-118Selective inhibitor · Breast CancerReviewScientificEvidenceNovelty3D ReadinessCommercial PotentialStrengthen evidence
OGC-IM-009Immunomodulator · MelanomaNeeds EvidenceScientificEvidenceNovelty3D ReadinessCommercial PotentialComplete missing data
OGC-NS-321CNS penetrant agent · GlioblastomaHigh PriorityScientificEvidenceNovelty3D ReadinessCommercial PotentialConfirm penetration assay
OGC-LU-104Targeted degrader · Lung CancerReviewScientificEvidenceNovelty3D ReadinessCommercial PotentialReview pathway evidence
Showing 1–5 of 10
1 / 2

Priority Matrix

Scientific evidence × translational potential · select a candidate

Commercial / translational potential ↑
Validate FurtherPrioritiseLow PriorityMonitor
Scientific evidence →

Triage Funnel

Portfolio progression

Asset Intake
245
Screened
72
Triage Review
24
High Priority
8
Validation Ready
6

Evidence Gap Analysis

Tracked actions for selected candidate

3 open
High
Missing replicate confirmation3D response study · Dr. S. Mokoena

Run independent replicate assay

Medium
Limited PK/PD evidencePreclinical package · Dr. J. Patel

Link exposure and pathway response

Medium
Insufficient pathway validationMechanism review · Dr. L. Chen

Add orthogonal pathway assay

Low
Dataset metadata incompleteDataset QC · Imaging Core

Complete instrument metadata

High
No independent reviewer sign-offGovernance · Scientific Review Board

Assign independent reviewer

TRIAGE REVIEW

OGC-2401

Novel small molecule · Breast Cancer

Priority RecommendedHigh Priority

Triage Summary

Scientific and commercial assessment for review. A human reviewer must confirm the evidence and priority decision.

Why this score?

Scientific Score92
Evidence Score85
Novelty88
3D Readiness91
Commercial Potential84
Scores combine component signals shown from the table. They are research values, not validated calculations.

Evidence Strengths

Selective activity in 3D TNBC models

Strong biological relevance

Consistent image-derived response trend

Evidence Gaps

Missing replicate confirmation

Limited PK/PD evidence

Insufficient pathway validation

Uncertainty

Low uncertainty

Reviewer Notes

Replicate confirmation and independent review remain necessary before validation approval.

Assigned: Dr. S. Mokoena

Recommended Next Action

Continue 3D validation

OSIEL recommendation · human approval required.

Open Asset Workspace Inspect Evidence with OSIELSend to 3D Validation
AI recommendation ≠ human approval